
    
      After being informed about the study and potential risks, all patients giving written
      informed consent will be screened for eligibility. Hospitalized patients who are 12-18 years
      of age and who are receiving background antibiotic treatment for uncomplicated urinary tract
      infection, complicated urinary tract infection, acute pyelonephritis, or complicated
      intraabdominal infection, and who meet eligibility requirements will receive a single 1000 mg
      IV dose of sulopenem on Day 1. The following day, patients will receive a single dose of 500
      mg of sulopenem etzadroxil and 500 mg of probenecid given orally as a bilayer tablet. During
      treatment, pharmacokinetic samples will be collected and patients will be monitored for
      safety and tolerability.
    
  